Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are at least 12 years of age at date of written informed consent/assent.~* Subjects who have given written informed consent or, for subjects aged 12-17 years (inclusive), have given written assent and whose parent/guardian has given written informed consent.~* Subjects with hereditary mild to severe Factor X deficiency (\<20% basal FX activity), including previously untreated subjects OR those currently treated with Fresh Frozen Plasma (FFP), Prothrombin Complex Concentrate (PCC) or factor IX/X concentrate by prophylaxis or on demand.~* Subjects who are to undergo surgery in which the investigator believes a factor X concentrate will be required due to a prior history of unusual bleeding either spontaneously or after surgery or trauma in the absence of treatment with a factor X containing product.~* Pregnant subjects undergoing obstetric delivery (including Caesarean surgery and vaginal delivery) may enter the study. Female subjects of child-bearing potential must have a negative result on a human chorionic gonadotropin-based pregnancy test. If a female subject is or becomes sexually active, she must practice contraception by using a method of proven reliability for the duration of the study.~Exclusion Criteria:~* Subjects who are required or expected to take other factor X containing medications during or after surgery.~* Subjects with a history of inhibitor development to FX or a detectable inhibitor to FX (≥0.6 BU) on the Nijmegen-Bethesda assay at screening. Obtaining a FX inhibitor result at screening is not mandatory if the subject is to undergo emergency surgery and the local laboratory is unable to perform the analyses prior to the surgical procedure.~* Subjects with thrombocytopenia (platelets \< 50 x 109/L).~* Subjects who have clinically significant renal disease (creatinine \>200µmol/L).~* Subjects who have clinically significant liver disease (ALT levels greater than three times the upper limit of normal).~* Subjects known to have other coagulopathy or thrombophilia.~* Subjects who are currently participating or have participated in another trial within the last 30 days, with the exception of the BPL Factor X PK study (protocol number Ten01).~* Female subjects who are lactating.~* Subjects who have known or suspected hypersensitivity to the investigational medicinal product or its excipients.~* Subjects known to have abused chemicals or drugs within the past 12 months.~* Subjects with a history of unreliability or non-cooperation.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FACTOR X (Type: EXPERIMENTAL): Human Coagulation Factor X

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues